VA launches – The U.S. Department of Veterans Affairs has started a randomized, placebo-controlled clinical trial testing MDMA-assisted therapy for about 80 veterans at VA facilities in Providence, Rhode Island, and West Haven, Connecticut. The study will compare MDMA-assis
A new clinical trial is beginning inside the Veterans Affairs system—one that places MDMA-assisted therapy under the same kind of scrutiny the agency uses for any high-stakes medical question.
The U.S. Department of Veterans Affairs has launched a study to examine whether MDMA-assisted therapy could help veterans suffering from severe mental health conditions. including post-traumatic stress disorder (PTSD) and alcoholism. The trial is among the federal government’s most significant efforts yet to examine psychedelic-assisted treatment for veterans. as officials confront rising rates of trauma. addiction. and suicide.
The trial’s design is built for comparison. It is randomized and placebo-controlled, with about 80 veterans enrolled at VA facilities in Providence, Rhode Island, and West Haven, Connecticut. Participants will either receive MDMA-assisted therapy or identical psychotherapy, paired with an “active placebo” for comparison.
“This trial represents an important step in safely evaluating new approaches and innovations to treat Veterans with severe mental health conditions,” VA Secretary Doug Collins said in the official VA press release.
For the VA, veterans aren’t just one of many groups potentially affected by PTSD. PTSD remains one of the most persistent mental health challenges facing U.S. veterans, particularly among those who served in combat. The VA says many patients do not fully respond to existing treatments such as antidepressants or traditional psychotherapy—an opening that has fueled interest in alternative approaches when conditions are severe or treatment-resistant.
MDMA-assisted therapy, however, remains a lightning rod in American public life.
In the United States. MDMA is classified as a Schedule I controlled substance. a designation that indicates the federal government considers it to have a high potential for abuse and no accepted medical use. The debate intensified after the Food and Drug Administration declined to approve MDMA-assisted therapy for PTSD in 2024. saying additional research and evidence were needed. Medical organizations and advisory panels have echoed that position. warning that more high-quality evidence is required before the treatment can be broadly recommended.
Concerns are not limited to legal status. Experts have raised questions about potential misuse, safety risks, and unknown long-term effects. Supporters argue the clinical version of medical MDMA administration is fundamentally different from recreational drug use.
The trial’s focus is on a tightly controlled version of treatment: MDMA-assisted therapy combines carefully managed doses of MDMA with structured psychotherapy sessions. Unlike traditional medications taken daily. MDMA is administered only a few times during treatment. acting as a catalyst to enhance therapy rather than replacing it.
The approach is often described in three stages. First is preparation. where patients receive two to three sessions with their therapists to build trust and feel safe emotionally before they take the MDMA dose. Next comes MDMA dosing: patients receive two to three MDMA-assisted sessions in a non-clinical environment. spaced one month apart. with a dose of MDMA while a therapist provides support as the patient talks openly and reflects. Each dosing session lasts between six and eight hours. Afterward is integration. with up to three sessions in which patients learn how to apply new understanding or ways of thinking to everyday life.
Researchers say MDMA’s effects in this setting relate to changes in brain chemistry—boosting serotonin. norepinephrine. dopamine. and oxytocin. which can increase emotional openness and trust. while reducing activity in brain regions involved in processing fear and danger that often remain heightened in people with PTSD.
That shift is described by scientists as creating a “therapeutic window,” allowing patients to revisit traumatic memories without being overwhelmed by anxiety and fear.
Dr. Michael Mithoefer, a leading researcher in the field, put it this way: “MDMA doesn’t do the work for the patient. It makes it easier for them to do the work themselves.”
The VA’s decision to run the trial also rests on a body of earlier research suggesting the therapy may be unusually effective for PTSD—especially in patients who haven’t responded to conventional treatments. In Phase 3 clinical trials led by the Multidisciplinary Association for Psychedelic Studies. results were described as striking: around 67 to 71 percent of patients who received MDMA-assisted therapy were no longer considered to have PTSD following the treatment.
Still, for a federal agency, the immediate question is safety—and how carefully the treatment is administered. The VA says safety will be paramount. The trial will use pharmaceutical-grade MDMA in a controlled environment, with strict protocols developed in coordination with the FDA.
The MDMA trial is also part of a broader VA effort to tackle mental health issues. The agency is currently involved in 19 psychedelic-related studies, backed by more than $23 million in funding.
For veterans, the stakes are not abstract. The VA reported that, each year, more than 6,000 veterans take their own lives. With those numbers in mind. the urgency for treatments that work—especially for people who have exhausted other options—has shaped the agency’s interest in exploring new approaches.
Whether MDMA-assisted therapy will win regulatory approval remains uncertain. But the VA’s new trial signals a significant shift in how trauma treatment is being tested inside the federal system—one that could change the conversation for veterans if the results prove durable.
VA veterans MDMA-assisted therapy PTSD alcoholism clinical trial FDA Schedule I Doug Collins Providence Rhode Island West Haven Connecticut
So they’re just gonna give veterans ecstasy? That seems insane.
I don’t get why they need a “trial” when everyone online already says it works. If it helps PTSD then let them do it, like… why wait. Also placebo? how is that even fair?
Randomized placebo-controlled sounds like they might be denying people the real thing for the study. Like, what if the veterans actually need MDMA and they just get regular therapy and a pill that does nothing. And Providence/West Haven… isn’t West Haven where a bunch of stuff already happened? I’m probably mixing it up but still.
As if veterans don’t have enough problems. Now it’s “active placebo” like that’s comforting. I read “PTSD and alcoholism” and immediately thought it’s gonna be some kind of government-approved party drug program. Maybe it’s medical, sure, but the headline makes it sound messy and risky. I just hope they’re not overlooking addiction side effects or whatever.